This Women's Month, we celebrate a groundbreaking advancement in women’s health! Discover the incredible interim results from the Phase 3 PURPOSE 1 trial, where Gilead’s injectable HIV-1 capsid inhibitor, Lenacapavir, demonstrated 100% efficacy in preventing HIV among cisgender women. Learn how this innovation aligns with The Aurum Institute’s commitment to transforming HIV prevention and improving health outcomes.
Негізгі бет Aurum on Lenacapavir’s Breakthrough in HIV Prevention for Women
Пікірлер